Book a demo

Continuous Crystallization Patents: Leaders, Trends & White Space 2026

Continuous Crystallization Patents: Leaders, Trends & White Space 2026
https://www.patsnap.com/resources/blog/rd-blog/continuous-crystallization-of-active-ingredients-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Pharmaceutical Manufacturing
Continuous Crystallization of Active Ingredients: Patents, Leading Filers and Open Claim Space
  • Filing has fallen 79% from 2021 to 2024, the last complete year in scope — a sharp pullback from the 2017 peak of 67 filings, not a plateau.
  • The leader holds 107 records, but the top 5 assignees combined account for only 16.3% of all 1,307 records — no single owner controls the field.
  • Separation and reaction-engineering classes (B01D, B01J) outweigh medicinal-preparation claims (A61K), showing most of the documented invention sits in the crystallizer hardware and process control, not the molecule.
Get a prior-art report on your approach
1,307
Published Records
16%
Top-5 Share of All Records
-79%
Filing Growth 2021→2024
US
Leading Jurisdiction

Filing growth compares 2021 (43 records) with 2024 (9) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,307 records in scope (CR5), not by the ranked leaders only.

Published byPatsnap Research··7 min readSourced from Patsnap Eureka
Overview

What this landscape covers

Continuous crystallization replaces batch cooling or evaporative crystallizers with steady-state or plug-flow equipment that runs for extended periods without stopping to empty and reload. Patent activity in this dataset centers on the operational problems that keep such systems running: residence time control, encrustation and fouling management, startup transients, and slurry transfer between stages. The scope spans 1,307 published records filed between 2015 and mid-2026.

The dataset draws on documents indexed under mixed suspension crystallizer and continuous crystallization terminology, cross-referenced against process-engineering terms like plug flow crystallizer and steady state operation. That combination pulls in both pharmaceutical active-ingredient crystallization and adjacent process industries that share the same equipment vocabulary, which is visible in the IPC spread below.

Filing activity and technology composition, 2015–2026
  1. 1SUMITOMO METAL MINING CO LTD107
  2. 2MITSUBISHI CHEM CORP35
  3. 3PFIZER PROD INC27
  4. 4MITSUBISHI GAS CHEM CO INC22
  5. 5MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN EV22
  6. 6TOYOTA JIDOSHA KK21
  7. 7AE STALEY MANUFACTURING CO19
  8. 8SHELL INTERNATIONALE RESEARCH MAATSCHAPPIJ BV18
  9. 9GE HEALTHCARE AS18
  10. 10NEDERLANDSE ORG VOOR TOEGEPAST NATUURWETENSCHAPPELIJK ONDERZOEK TNO18
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Continuous Crystallization of Active Ingredients covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
The Data

Filing trend and technology composition

Two views of the same 1,307-record corpus: how filing activity has moved year over year, and which IPC subclasses the claims sit in.

Filing trend, 2017–2026

Filings peaked at 67 in 2017 and declined to 3 by 2026, though the two most recent years are still incomplete due to publication lag. The clearest complete-year comparison is 2021 (43 filings) against 2024 (9 filings) — a 79% drop over three years, and the figure this page's growth statement is built on.

Filing trend, 2017–20260204060806720172018201920202021202220232024202532026Most recent year is partial — publication lag means later filings are not yet visible.

IPC subclass composition

C07C (acyclic and carbocyclic compounds) and B01D (separation processes) each cover roughly a quarter of the 1,307 records, with B01J (catalytic and physical processes) close behind. A61K (medicinal preparations) and C07D (heterocyclic compounds) sit lower, at under 10% each — evidence that the patent activity in this search concentrates on the crystallizer process itself rather than on the pharmaceutical molecule being crystallized. Records can carry more than one class, so these shares sum above 100%.

IPC subclass compositionC07C · Acyclic & carbocyclic compounds32324.7%B01D · Separation processes (filtrati…30223.1%B01J · Chemical/physical processes & …20315.5%H01M · Batteries, cells & fuel cells13210.1%A61K · Medicinal preparations1279.7%C07D · Heterocyclic compounds1259.6%C01B · Non-metallic elements & inorga…1098.3%C01G · Compounds of other metals1078.2%Other1,07282.0%

Shares are the percentage of the 1,307 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.

Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Continuous Crystallization of Active Ingredients covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.

Go deeper on Continuous Crystallization of Active Ingredients with Eureka

This page is one run against one query. Ask Eureka your own question about continuous crystallization of active ingredients and every answer comes back with the patent numbers behind it.

Try Eureka
Key Patents

Most-cited records and a representative filing

Representative Filing
US20170312795A12017-11-02

Anti-fouling control for plug flow crystallizers (US20170312795A1)

PURDUE RESEARCH FOUNDATION

Filed by Purdue Research Foundation, this application describes a plug flow crystallizer with independently controlled heating/cooling elements along its channel, run by a controller that implements a temperature profile designed to grow crystals in one segment and dissolve encrustation in another — addressing fouling directly inside the flow path rather than through downstream cleaning cycles.Filed 2017-11-02. Encrustation control is one of the recurring operational problems this search string was built to surface.

US20170312795A1 — patent drawing 1US20170312795A1 — patent drawing 2
View full record
Most-cited patents in this landscape
#Publication no.Patent titleCitations
1US3234258ASulfation of alpha olefins430
2US5314506ACrystallization method to improve crystal structure and size321
3US5175355AImproved process for recovery of purified terephthalic acid238
4US3931305ATerephthalic acid recovery by continuous flash crystallization190
5US3452088ATerephthalic acid recovery153
6US5756833ACatalytic purification and recovery of dicarboxylic aromatic acids143
7US4500732AProcess for removal and recycle of p-toluic acid from terephthalic acid crystallizer solvent132
8US20120270107A1Nickel-cobalt-manganese complex hydroxide particles and method for producing same, positive electrode active …116
9US5738834ASystem for removal of hydrogen sulfide from a gas stream113
10EP0419400A2Process for crystallization of polyethylene naphthalate110

Citation counts favor older documents simply because they have had more time to be cited; treat this as a signal of influence within the searched corpus, not of current commercial relevance.

Each row carries its publication number; clicking a row searches Eureka by that number.

Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Continuous Crystallization of Active Ingredients covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself

Put your own technology through the same analysis

 
Where to run it
Fastest

Eureka on the web

When you want the answer in the next five minutes.

The agent works the prompt against patents and technical literature, citing every source.

Run your analysis now →
For builders

MCP server & REST API

When it has to run inside your own pipeline.

Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.

Browse MCP servers →
Insights

What the numbers say

Three figures from the dataset that change how you should read the rest of the page.

Concentration
16.3%
of 1,307 records held by top 5

No single assignee dominates

The leading assignee holds 107 records, but the next four combined bring the top-5 share to only 16.3% of all 1,307 records in scope. The top 10 combined reach 23.5%. That leaves a long tail of single- and few-filing entrants holding most of the field.

Ranking covers 100 assignees, the full set the data endpoint returns.
Filing momentum
-79%
2021 to 2024 (complete years)

Activity has pulled back sharply since 2017

From a 2017 peak of 67 filings, activity fell to 43 in 2021 and 9 by 2024 — a 79% drop across those three complete years. 2025 and 2026 figures are still filling in under an approximate 18-month publication lag, so they should not yet be read as a continuation of the decline.

Peak year: 2017 at 67 filings.
Technology split
24.7% vs 9.7%
C07C share vs A61K share of records

Process hardware outweighs the active ingredient

C07C and B01D each cover roughly a quarter of the 1,307 records, while A61K (medicinal preparations) sits at 9.7%. Most of the documented claim space addresses the crystallizer and its operation, not the drug substance being made.

Records may carry multiple IPC classes; shares sum above 100%.
Eureka AI Agent
Looking for what nobody has claimed yet?

Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to continuous crystallization of active ingredients, with the prior art for and against each one.

Find the white space →
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Continuous Crystallization of Active Ingredients covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players

Who holds the ground, and where it opens up

The ranked leaders account for a modest share of total filings, and recent-year momentum has gone quiet across the assignees who built the largest positions.

Leader position
107 records
single-assignee high

A clear leader, but not a lock on the field

The top-ranked assignee's 107 records are well ahead of fifth place (22) and tenth place (18), showing a steep drop-off rather than a cluster of comparable rivals just behind the leader.

Fifth place: 22 records. Tenth place: 18 records.
Recent activity
0 in latest year
across several leading assignees

Momentum has gone quiet at the top

Several of the assignees with the largest historical positions show zero filings in the latest year of the dataset. That is consistent with the broader decline from the 2017 peak, though the most recent years are still incomplete due to publication lag.

Applies to multiple top-ranked assignees, not just one.
Collaboration
10 pairs
co-assignee pairings identified

Co-filing is limited and concentrated

Only 10 co-assignee pairs appear in the dataset, with the strongest pairings repeating between the same handful of organisations. Co-development is the exception here, not the norm.

Strongest pairs recur at 4-6 shared records.
🔍
Under-claimed branches worth checking before filing
Sub-areas where the IPC mix and citation pattern suggest thinner prior art than the headline classes.
slurry transfer between crystallizer stagesstartup transient control in plug flow systemsin-line encrustation detection and cleaningmulti-stage residence time distribution tuning
Rank all filers by momentum →
Recent-year filing momentum by assignee
AssigneeRecent yearYoY
Sumitomo Metal Mining Co., Ltd.0
Mitsubishi Chemical Corporation0
Pfizer Products Inc.0
Shell Internationale Research Maatschappij B.V.0
A.E. Staley Manufacturing Co.0
Max Planck Gesellschaft zur Förderung der Wissenschaften e.V.0
Mitsubishi Gas Chemical Company, Inc.0
GE Healthcare AS0
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Continuous Crystallization of Active Ingredients covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next

Where to take this next

The landscape points to specific next steps depending on whether you are scoping freedom to operate or looking for a filing position.

Check the under-claimed branches before drafting claims

Slurry transfer, startup transients and in-line fouling detection show up less in the top-cited records than crystallizer hardware itself, suggesting room for narrower process claims.

Explore white space in Eureka

Watch for a rebound once 2025-2026 data settles

Because publication lags filing by around 18 months, the apparent decline through 2026 needs another filing cycle before it can be called a real slowdown rather than a data gap.

Track filing trends in Eureka
Source: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Continuous Crystallization of Active Ingredients covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ

Common questions about this landscape

Answers are grounded in the same dataset. Derived from a Patsnap search on Continuous Crystallization of Active Ingredients covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP

Research Continuous Crystallization of Active Ingredients in depth with Eureka

Go past this page: query the whole continuous crystallization of active ingredients corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.

Try Eureka

Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.

Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.

Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.

Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.